Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight

The liquid biopsy market size in cancer diagnostics is experiencing rapid growth due to advancements in non-invasive testing technologies. These tests, which analyze blood or other bodily fluids for cancer-related biomarkers, offer a less invasive alternative to traditional tissue biopsies. Increasing cancer prevalence, rising demand for early detection, and continuous innovations in genomics and biotechnology are driving market expansion.

/EIN News/ -- New York, USA, April 23, 2025 (GLOBE NEWSWIRE) -- Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of  ~17%  by 2032 with Advancements in Non-Invasive Testing | DelveInsight

The liquid biopsy market size in cancer diagnostics is experiencing rapid growth due to advancements in non-invasive testing technologies. These tests, which analyze blood or other bodily fluids for cancer-related biomarkers, offer a less invasive alternative to traditional tissue biopsies. Increasing cancer prevalence, rising demand for early detection, and continuous innovations in genomics and biotechnology are driving market expansion.

DelveInsight’s Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading liquid biopsy companies’ market shares, challenges, liquid biopsy market drivers, barriers, trends, and key liquid biopsy companies such as Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc., and others in the market.

Liquid Biopsy in Cancer Diagnostics Overview

Liquid biopsy is a minimally invasive technique that detects and monitors cancer through blood or other bodily fluids, analyzing circulating tumor cells, cell-free DNA, or exosomes shed by tumors. Unlike traditional tissue biopsies, it offers real-time insights into tumor genetics, aiding in early diagnosis, treatment monitoring, and detection of residual disease or recurrence—especially valuable when tissue is inaccessible or frequent sampling is needed. By capturing the tumor's evolving molecular profile, liquid biopsy supports personalized treatment, identifies actionable mutations, reveals resistance mechanisms, and benefits from advances in technologies like next-generation sequencing and digital PCR, enhancing its role in precision oncology.

Liquid Biopsy in Cancer Diagnostics Regional Market Insights

North America is projected to hold a major share of the liquid biopsy market in cancer diagnostics. This dominance is attributed to factors such as the rising incidence of cancer, a strong emphasis on oncology research, favorable government initiatives supporting liquid biopsy advancements, and a supportive environment for product innovation and commercialization.

Within North America, in 2024, the US liquid biopsy market contributed 87% of the region's revenue. A primary driver of this high adoption rate for liquid biopsy products and services in the US is the substantial cancer burden in the country.

Europe follows closely, with Germany, France, and the UK leading in the integration of liquid biopsy into routine clinical practice, supported by favorable government policies and an aging population prone to cancer. Meanwhile, Asia-Pacific is emerging as a high-growth region, especially in countries like China, Japan, and India, fueled by rising cancer incidence rates, increasing awareness, and improvements in diagnostic technologies.

Regional disparities in market development are primarily influenced by healthcare accessibility, reimbursement frameworks, and regulatory environments. North America enjoys a significant head start due to its strong network of biotech firms and collaborations between diagnostic companies and academic institutions. 

In contrast, Latin America and parts of the Middle East and Africa are in earlier stages of adoption, facing challenges such as limited infrastructure and a lack of trained professionals. However, with growing investments and international collaborations, these regions present untapped opportunities for market expansion. Overall, regional insights highlight the importance of localized strategies to address the diverse challenges and unlock the full potential of liquid biopsy in cancer diagnostics worldwide.

To know more about why North America is leading the market growth in the liquid biopsy market, get a snapshot of the Liquid Biopsy for Cancer Diagnostics Market Outlook

Recent Developments in the Liquid Biopsy in Cancer Diagnostics Market

• In March 2025, Belay Diagnostics partnered with GenomOncology (GO), a precision medicine software provider offering data-driven solutions to enhance cancer care. To optimize the tertiary analysis of its Summit test and comprehensive DNA panel, Belay Diagnostics has integrated the GO Pathology Workbench into its variant interpretation and analysis processes. Designed with specialized clinical applications, the GO Pathology Workbench allows the Belay Diagnostics team to efficiently process thousands of samples each month. This customized platform supports accurate variant interpretation and informed treatment decision-making.
• In December 2024, PanGIA Biotech, a trailblazer in liquid biopsy technology, announced its first global partnership through a collaboration with Canary Oncoceutics. This alliance brings the launch of the PanGIA Prostate Assay to market—an AI-powered, urine-based liquid biopsy designed for prostate cancer detection—making its commercial debut in India.
• In August 2024, Labcorp announced that it had received De Novo marketing authorization from the FDA for PGDx elio plasma focus Dx — the first and only kitted liquid biopsy test for pan-solid tumors available in the industry.
• In May 2024, Mercy BioAnalytics, Inc., a leader in extracellular vesicle-based liquid biopsy for early cancer detection, received Breakthrough Device Designation from the FDA for its Mercy Halo Ovarian Cancer Screening Test, intended for use in asymptomatic, postmenopausal women.

To read more about the latest highlights related to the liquid biopsy market, get a snapshot of the key highlights entailed in the Liquid Biopsy Techniques

Key Players in the Liquid Biopsy in Cancer Diagnostics Market

The liquid biopsy market is rapidly evolving, driven by the demand for minimally invasive, accurate, and real-time monitoring tools in oncology. Key players in liquid biopsy market include major diagnostics and biotechnology companies such as Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc., QIAGEN, Lucence Health Inc., Personal Gemone Diagnostics Inc., SAGA Diagnostics, Agena Bioscience Inc., The Menarini Group, MiRXES Pte Ltd., and others.​

These liquid biopsy companies are at the forefront of innovation, leveraging next-generation sequencing (NGS), digital PCR, and advanced bioinformatics to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from blood and other bodily fluids. Their platforms are increasingly being adopted in both clinical and research settings for early cancer detection, treatment selection, monitoring therapeutic response, and identifying resistance mechanisms.

Which MedTech key players in the liquid biopsy market are set to emerge as the trendsetter explore @ Top Liquid Biopsy Companies

Liquid Biopsy in Cancer Diagnostics Market Key Factor Analysis

Liquid Biopsy in Cancer Diagnostics Market Drivers

The liquid biopsy market in cancer diagnostics is being driven by several key factors:

• Rising incidence of various cancers, increasing the need for effective diagnostic tools.
• Growing demand for minimally invasive procedures, as patients and healthcare providers prefer less invasive and more comfortable diagnostic options.
• The increasing prominence of precision medicine, which focuses on tailoring treatments based on individual genetic profiles, is boosting the use of liquid biopsy in personalized cancer care.
• Ongoing technical innovations in product development, including:
  • Advancements in genomics
  • Improvements in sequencing technologies
  • Progress in bioinformatics

These innovations are enhancing the sensitivity, accuracy, and speed of liquid biopsy tests. Collectively, these factors are contributing to the growing importance of liquid biopsy in revolutionizing cancer diagnostics.

Liquid Biopsy in Cancer Diagnostics Market Restraints and Challenges

The liquid biopsy market faces several challenges, including the risk of false results, such as false positives and false negatives, which can arise due to factors like low concentrations of tumor DNA in blood samples, technical limitations, or biological variations. Additionally, the lack of standardization in procedures, including sample collection, processing, and testing methodologies, creates variability in results, making it difficult to ensure consistent and reliable outcomes across different laboratories and healthcare systems. Overcoming these obstacles is crucial for improving the accuracy and clinical utility of liquid biopsy tests.

Liquid Biopsy in Cancer Diagnostics Market Opportunities

The liquid biopsy market in cancer diagnostics presents significant opportunities, particularly due to the limited current utilization in clinical settings. Despite its potential, the adoption of liquid biopsy in routine clinical practice remains underdeveloped, offering room for market growth as awareness and integration improve. Additionally, expanding the reach of liquid biopsy technologies in emerging economies presents a promising opportunity. 

As these regions experience advancements in healthcare infrastructure and greater access to diagnostic tools, liquid biopsy can be integrated into cancer detection protocols, providing non-invasive and cost-effective solutions to address the rising demand for advanced diagnostics.

Get a sneak peek at the liquid biopsy market dynamics @ Global Liquid Biopsy Market Intelligence

Report Metrics	Details
Coverage	Global
Study Period	2022–2032
Liquid Biopsy in Cancer Diagnostics Market CAGR	~17%
Liquid Biopsy in Cancer Diagnostics Market Size in 2032	USD 19.24 Billion
Key Liquid Biopsy in Cancer Diagnostics Companies	Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc., QIAGEN, Lucence Health Inc., Personal Gemone Diagnostics Inc., SAGA Diagnostics, Agena Bioscience Inc., The Menarini Group, MiRXES Pte Ltd., among others

Liquid Biopsy in Cancer Diagnostics Market Assessment

• Liquid Biopsy in Cancer Diagnostics Market Segmentation
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Type: Product Type (Instruments and Reagents & Kits) and Services
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Sample Type: Blood, Urine, and Saliva
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Biomarker Type: Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Cancer Type: Lung Cancer, Breast Cancer, Colon Cancer, and Others
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Technique: Polymerase Chain Reaction and Next Generation Sequencing
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By End User: Hospitals, Diagnostic Centers, and Others
  • Liquid Biopsy in Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing the liquid biopsy market by 2032? Click to get a snapshot of the In-vitro Diagnostic Liquid Biopsy Testing

Table of Contents 

1	Liquid Biopsy in Cancer Diagnostics Market Report Introduction
2	Liquid Biopsy in Cancer Diagnostics Market Executive Summary
3	Competitive Landscape
4	Regulatory Analysis
5	Liquid Biopsy in Cancer Diagnostics Market Key Factors Analysis
6	Liquid Biopsy in Cancer Diagnostics Market Porter’s Five Forces Analysis
7	Liquid Biopsy in Cancer Diagnostics Market Layout
8	Liquid Biopsy in Cancer Diagnostics Market Company and Product Profiles
9	KOL Views
10	Project Approach
11	About DelveInsight
12	Disclaimer & Contact Us

Related Reports

Cancer Diagnostics Market

Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cancer diagnostics companies, including Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, among others.

AI in Cancer Diagnostics Market

AI in Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AI in cancer diagnostics companies, including iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, among others.

Blood Cancer Diagnostics Market

Blood Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key blood cancer diagnostics companies, including BD, Abbott, Agilent Technologies, Inc., Adaptive Biotechnologies, F. Hoffmann-La Roche Ltd., Invivoscribe, Inc., NeoGenomics Laboratories, Inivata Ltd., Lucence Health Inc., BioFluidica, SkylineDx, MedGenome, Xian Tianlong Science and Technology Co.,Ltd., Cepheid, Abingdon Health, among others.

Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer diagnostics companies, including Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCiné, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.

Prostate Cancer Diagnostics Market

Prostate Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer diagnostics companies, including F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us
                    
                    Shruti Thakur 
                    
                    info@delveinsight.com 
                    
                    +14699457679
                    
                    https://www.delveinsight.com/medical-devices